1-9 of 9
Mark B. Geyer, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Aaron D Goldberg, MDPhD, Mark B. Geyer, MD, Jonathan Kell, MD, Eros Di Bona, MD, Timothy S. Pardee, MDPhD, Rupali Bhave, MD, Michael R. Grunwald, MD, Giovanni Marconi, MD, Yijia Wang, MD MPH, Asif Pathan, PhD RPh, Boo Messahel, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-139898
Published: 2020
Journal Articles

Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy As Consolidation and Maintenance Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction

Mark B. Geyer, MD, Amber C. King, PharmD, BCOP, Justin C. O'Brien, Jae H. Park, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45.
https://doi.org/10.1182/blood-2020-137016
Published: 2020
Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Maximilian Stahl, MD, Andriy Derkach, PhD, Christopher Famulare, MS, Christina Cho, MD, Sean Devlin, PhD, Noushin Farnoud, PhD, Kamal Menghrajani, MD, Minal A Patel, MPH, Sheng F Cai, MDPhD, Mark B. Geyer, MD, Andrew Dunbar, MD, Zachary D. Epstein-Peterson, MD, Erin McGovern, BA, Jessica Schulman, BSc, Jacob L Glass, MDPhD, Justin Taylor, MD, Aaron D Viny, MDMS, Eytan M. Stein, MD, Bartlomiej Getta, FRCPA, FRACP, MBBS, Maria E. Arcila, MD, Ross L. Levine, MD, Juliet Barker, MBBS, Brian C. Shaffer, MD, Esperanza B. Papadopoulos, MD, Boglarka Gyurkocza, MD, Miguel-Angel Perales, MD, Omar Abdel-Wahab, MD, Elli Papaemmanuil, PhD, Sergio A. Giralt, MD, Yanming Zhang, MD, Mikhail Roshal, MD PhD, Martin S. Tallman, MD, Aaron D Goldberg, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-137552
Published: 2020
Journal Articles

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients

Chaitra S. Ujjani, MD, Lindsey E. Roeker, MD, Mazyar Shadman, MD MPH, Kate J Whitaker, BA, Allison P. Jacob, Mark B. Geyer, MD, Colleen Dorsey, BSN, RN, Andrew D. Zelenetz, MD PhD, Anthony R. Mato, MDMSCE
Journal: Blood
Blood (2019) 134 (Supplement_1): 1758.
https://doi.org/10.1182/blood-2019-124002
Published: 2019
Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Alison J. Moskowitz, MD, Paola Ghione, MD, Eric D Jacobsen, MD, Jia Ruan, MD PhD, Jonathan H. Schatz, MD, Sarah Noor, MD, Patricia Myskowski, Helen Hancock, ANP, Theresa Davey, MMSc, PA-C, Obadi Obadi, Carlissa Onwasigwe, MPH, Nivetha Ganesan, MPH, Lauren Pomerantz, BS, Christine Jarjies, MS, Priyadarshini Kumar, Allison Sigler, Mark B. Geyer, MD, Ariela Noy, MD, David J. Straus, MD, Travis Hollmann, MD, Ahmet Dogan, MD PhD, Natasha Galasso, Giorgio Inghirami, MD, David M. Weinstock, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4019.
https://doi.org/10.1182/blood-2019-125017
Published: 2019
Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3887.
https://doi.org/10.1182/blood-2019-128506
Published: 2019
Journal Articles

Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss

Xiaochuan Yang, Amber C. King, PharmD, BCOP, Charlene C. Kabel, PharmD, Christopher J. Forlenza, MD, Jae H. Park, MD, Mark B. Geyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3888.
https://doi.org/10.1182/blood-2019-125165
Published: 2019
Journal Articles

Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia

Ryan J. Daley, PharmD, Sridevi Rajeeve, MD, Charlene C. Kabel, PharmD, Jeremy J. Pappacena, PharmD, BCOP, Sarah E. Stump, PharmD, BCPS, BCOP, Jessica A. Lavery, MS, Martin S. Tallman, MD, Mark B. Geyer, MD, Jae H. Park, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3816.
https://doi.org/10.1182/blood-2019-124727
Published: 2019
Journal Articles

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Rachel Bolanos, PhD MPH, Kelly Velasco, PharmD, Huakang Tu, PhD, Faraz Zaman, MD, Mark B. Geyer, MD, Jae H. Park, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5079.
https://doi.org/10.1182/blood-2019-122745
Published: 2019